Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
The Long Run with Luke TimmermanShow Notes
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
More from The Long Run with Luke Timmerman
Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.
Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.